Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wang

Showing results (331-340 of 675) with videos related to

Pageof 68
Sort By:
Lasers in Surgery and Medicine|January 16, 2024
Novel 40 µm spot size 3050/3200 nm DFG laser versus CO<sub>2</sub> laser for laser-assisted drug deliveryParita T Suwan, Ga Ram Ahn, Roger Sumner, et al.
Haematologica|September 5, 2024
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trialTycel Phillips, Michael Wang, Tadeusz Robak, et al.
Plos One|April 29, 2024
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphomaImani Bijou, Yang Liu, Dong Lu, et al.
American Journal of Clinical Oncology|February 9, 2018
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma)Dongfeng Zeng, Aakash Desai, Fangfang Yan, et al.
Elife|August 3, 2022
Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimationShouhao Zhou, Xinyi Liu, Xinying Fang, et al.
Haematologica|April 11, 2020
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphomaLifu Wang, Guilin Tang, L Jeffrey Medeiros, et al.
Neurospine|January 9, 2022
Utility of the MISDEF2 Algorithm and Extent of Fusion in Open Adult Spinal Deformity Surgery With Minimum 2-Year Follow-upBo Li, Gregory Hawryluk, Praveen V Mummaneni, et al.
Blood|August 17, 2011
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaRichard J Jones, Veerabhadran Baladandayuthapani, Sattva Neelapu, et al.
Cancer|November 1, 2008
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphomaMichael Wang, Luis Fayad, Fernando Cabanillas, et al.
Research Square|March 22, 2023
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphomaImani Bijou, Yang Liu, Dong Lu, et al.
Pageof 68

Showing results (331-340 of 675) with videos related to

Sort By:
Pageof 68
Lasers in Surgery and Medicine|January 16, 2024
Novel 40 µm spot size 3050/3200 nm DFG laser versus CO<sub>2</sub> laser for laser-assisted drug deliveryParita T Suwan, Ga Ram Ahn, Roger Sumner, et al.
Haematologica|September 5, 2024
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trialTycel Phillips, Michael Wang, Tadeusz Robak, et al.
Plos One|April 29, 2024
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphomaImani Bijou, Yang Liu, Dong Lu, et al.
American Journal of Clinical Oncology|February 9, 2018
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma)Dongfeng Zeng, Aakash Desai, Fangfang Yan, et al.
Elife|August 3, 2022
Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimationShouhao Zhou, Xinyi Liu, Xinying Fang, et al.
Haematologica|April 11, 2020
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphomaLifu Wang, Guilin Tang, L Jeffrey Medeiros, et al.
Neurospine|January 9, 2022
Utility of the MISDEF2 Algorithm and Extent of Fusion in Open Adult Spinal Deformity Surgery With Minimum 2-Year Follow-upBo Li, Gregory Hawryluk, Praveen V Mummaneni, et al.
Blood|August 17, 2011
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaRichard J Jones, Veerabhadran Baladandayuthapani, Sattva Neelapu, et al.
Cancer|November 1, 2008
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphomaMichael Wang, Luis Fayad, Fernando Cabanillas, et al.
Research Square|March 22, 2023
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphomaImani Bijou, Yang Liu, Dong Lu, et al.
Pageof 68